ZephyrTel Welcomes Three New Companies into Its Portfolio of Software Products Serving the Global Telecommunications Sector
10.7.2018 15:00:00 EEST | Business Wire | Press release
ZephyrTel, a new ESW software company, dedicated to serving the global Telecommunications and Cellular industry, is pleased to announce it has acquired three new companies into its portfolio – VoltDelta, PeerApp and Mobilology, effective immediately.
ZephyrTel is building a world class Telco Practice, which provides a multi-solution and services proposition to the global Telco industry.
The firm’s objective is to offer Software and SaaS solutions across a Telco company’s IT estate; from infrastructure right across to customer experience. This, coupled with its high level of industry domain expertise, will enable ZephyrTel to offer consultancy on both business strategy, and technology execution.
Having already acquired several Telecom software companies, ZephyrTel is currently adding to its portfolio, at pace. Its newly acquired products will be marketed by their valued, familiar product names and sit under the ZephyrTel corporate brand. The company’s ambition is to build a Telco Software Group of circa $1 Billion in the medium term.
The software company will be utilising ESW’s state of the art software development and performance improvement processes, to offer the industrys’ highest levels of installation stability and throughput. Additionally, 24/7 support, and high quality global Services coverage, will enable ZephyrTel to deliver enhanced levels of business value for technology investment.
The firm aims to offer the lowest Total Cost of Ownership (TCO) and superior Customer Value through its established, “tried and tested”, Customer Value programmes.
ZephyrTel CEO, Mike Shinya, commented; ‘”We see a great opportunity to serve the global telecommunications software market, from smallest to the largest of companies. The acquisition of VoltDelta, PeerApp and Mobilogy will significantly strengthen our portfolio. It is a great privilege to bring these organisations and their customers, to the ZephyrTel family.”
About VoltDelta
VoltDelta delivers cloud and premise-based, multichannel contact centre solutions, intelligent automation and data-driven contact management to optimize the customer journey. VoltDelta rapidly tailors and integrates its solutions to enable customers to increase revenue, boost retention and reduce operating costs while taking advantage of proven scalability and reliability. VoltDelta is part of NewNet Communication Technologies. For more information, please visit: www.voltdelta.net.
About PeerApp Ltd
Founded in 2004, PeerApp delivers award-winning open content caching solutions, including content localisation and caching, live streaming delivery, application and data acceleration, smart traffic management, QoE enhancement and congestion relief across all networks. Local content delivery solutions help operators generate new revenue opportunities. For more information, visit www.peerapp.com.
About Mobilogy
Mobilogy, formerly Cellebrite Mobile Lifecycle, is a world leader in providing Operators, Retailers and Aftermarket Service (AMS) Providers, with advanced mobile lifecycle solutions to enhance the customer experience, improve satisfaction, reduce cost, and generate revenue. With delivery channels in-store, on-device, and over the web, mobile retailers can take advantage of Mobilogy's full suite of mobile lifecycle solutions: diagnostics, phone-to-phone content transfer, backup, restore and wipe, automated phone buyback, and application and content delivery. In addition, Mobilogy offers retailers monitoring, statistics and analysis of all activities. Mobilogy’s global leadership is demonstrated through its deployment of over 150,000 units at more than 200 mobile operators and retailers globally, representing well over 100,000 stores and handling hundreds of millions of transactions per year. For more information, visit www.mobilogy.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180710005025/en/
Contact information
ZephyrTel
Mike Shinya
CEO
mike.shinya@zephyrtel.com
or
Martyn
Lambert
SVP Products & Marketing
martyn.lambert@zephyrtel.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom